AMT-130 reaches FDA as uniQure targets first disease-modifying Huntington’s therapy

uniQure has moved its most valuable pipeline asset into a potentially transformative regulatory phase by submitting AMT-130 for accelerated approval in Huntington’s disease, months after uncertainty over the FDA pathway triggered one of the sharpest swings in the biotechnology company’s valuation. The filing gives uniQure a chance to bring the first approved therapy capable of slowing Huntington’s disease progression to market without first completing a conventional randomized Phase III efficacy trial. A parallel application has also been submitted in the United Kingdom, while uniQure is requesting Priority Review in the United States, potentially placing important regulatory decisions on the calendar within months. The company has simultaneously strengthened its balance sheet and begun preparing for commercialization, making AMT-130 increasingly central not only to its clinical strategy but also to its long-term business model. Investors remain cautious despite the milestone, with uniQure shares reversing an early gain and trading about 3% lower shortly before the September 2 close as attention shifted toward FDA acceptance, upcoming four-year data and the unusual external-control evidence supporting the application.

The regulatory submission rests on three-year Phase I/II results in which high-dose AMT-130 was associated with a 75% slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale compared with a propensity score-matched external control. That result was statistically significant, while a key measure of patients’ ability to function independently also showed a significant slowing of deterioration. The central question is now whether regulators consider those findings sufficiently robust to support accelerated approval of a permanently administered gene therapy in a progressive neurological disease with no approved disease-modifying treatment.

AMT-130 could create an entirely new Huntington’s disease treatment market if accelerated approval is granted

Huntington’s disease is an inherited neurodegenerative disorder caused by an expanded CAG repeat within the huntingtin gene. Patients progressively develop movement abnormalities, cognitive decline and psychiatric symptoms, while currently available treatments can address certain manifestations of the disease without slowing the underlying neurodegenerative process.

That absence of disease-modifying therapy gives AMT-130 an unusually significant first-mover opportunity. Rather than entering a market containing several established products with comparable mechanisms, uniQure could potentially introduce the first treatment specifically demonstrated to slow Huntington’s disease progression.

AMT-130, formally known as ifezuntirgene inilparvovec, uses an adeno-associated virus serotype 5 vector to deliver an artificial microRNA designed to reduce production of huntingtin protein. The gene therapy is administered once directly into the brain through MRI-guided stereotactic neurosurgery targeting the caudate and putamen, two regions substantially affected by Huntington’s disease.

The one-time administration creates an important commercial distinction from chronic medicines, but it also raises the complexity of any potential launch. uniQure would need specialized treatment centers capable of performing the neurosurgical procedure, trained physicians, carefully coordinated patient selection and reimbursement structures capable of supporting a high-value gene therapy.

That treatment model could limit initial access compared with conventional oral medication. However, the potential for durable modification of a fatal progressive disease could support a very different value proposition if longer-term clinical results continue showing sustained benefit.

uniQure estimates that approximately 75,000 people across the United States, Europe and the United Kingdom have Huntington’s disease. Not every patient would necessarily qualify for treatment under an eventual label, but even a subset could represent a significant rare-disease commercial opportunity.

Three-year disease-progression data carry unusually high weight because AMT-130 has no conventional Phase III efficacy trial

The regulatory application is unusual because AMT-130 has not advanced through the conventional sequence of an early-stage study followed by a large randomized Phase III efficacy trial. Instead, uniQure is asking regulators to rely principally on its Phase I/II results compared with external natural-history patients.

The pivotal three-year analysis evaluated 29 patients who had received AMT-130, including 17 in the high-dose group and 12 in the low-dose group. Outcomes were compared with patients selected from the large Enroll-HD natural-history database using propensity score matching intended to make the groups more comparable.

High-dose treatment was associated with a statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale. Total Functional Capacity, which measures the ability of patients to perform everyday activities and remain independent, showed a statistically significant 60% slowing of deterioration compared with matched controls.

Cerebrospinal fluid neurofilament light protein also declined by an average of approximately 8% from baseline at 36 months in the high-dose group. Neurofilament light is associated with neuronal injury and provides an additional biological measure alongside the clinical outcomes.

These findings have substantially increased confidence in the program, but the small number of treated patients remains an important limitation. An external-control comparison can reduce some differences between groups through statistical matching, yet it cannot fully reproduce the safeguards created by randomization and concurrent treatment of control patients.

That issue is particularly important for a therapy requiring an invasive procedure. Patients willing and able to undergo stereotactic gene therapy administration may differ in meaningful ways from broader natural-history populations, creating potential sources of bias that regulators will need to examine carefully.

The forthcoming four-year data could therefore influence sentiment even while the application is moving through regulatory review. uniQure expects to report follow-up on 24 patients from its initial high- and low-dose cohorts, providing another year of information on both durability and safety.

FDA reversal transformed AMT-130 from a delayed program into uniQure’s biggest near-term catalyst

The current regulatory position represents a major turnaround from the uncertainty surrounding AMT-130 earlier in 2026.

The FDA previously indicated that the available Phase I/II evidence compared with external controls would not be sufficient as the primary demonstration of effectiveness. Regulators recommended a new prospective randomized study using a sham neurosurgical control, a requirement that could have delayed a potential filing for several years. uniQure shares fell sharply when that position became public.

The situation changed after a subsequent Type B meeting. The FDA communicated that the existing three-year analysis could serve as the primary basis of a Biologics License Application under the accelerated approval pathway, provided uniQure also develops an appropriate confirmatory study. The company and agency also discussed using concurrent patients receiving standard-of-care management as the confirmatory control rather than subjecting participants to sham brain surgery.

That shift dramatically compressed the potential development timeline and triggered a major reassessment of uniQure’s valuation. Reuters reported that the company’s shares rose more than 75% when the revised FDA position was disclosed in June.

The reversal does not mean the FDA has predetermined the approval decision. Filing acceptance, accelerated approval eligibility and the ultimate benefit-risk assessment remain separate regulatory decisions, while the agency could request additional analyses or conclude that the external-control evidence is insufficient after reviewing the full application.

uniQure has requested Priority Review. If granted after the FDA accepts the application, the agency would generally target action within six months rather than the standard 10-month review timeline. The initial filing review itself is expected to take approximately 60 days.

A confirmatory study will remain important even if accelerated approval is granted. The FDA has indicated that such a study should be feasible within a reasonable timeframe and sufficiently advanced, potentially fully enrolled, around the time an accelerated approval decision is reached.

uniQure has built the financial runway to prepare for AMT-130 commercialization before the FDA decision

The regulatory progress comes after uniQure substantially strengthened its financial position. The company ended June with approximately $810.3 million in cash, cash equivalents and current investment securities after completing an upsized public offering that generated about $259 million in gross proceeds. Management expects the balance sheet to support operations into 2030, including preparation for a potential AMT-130 launch.

That runway reduces one of the most common risks facing clinical-stage biotechnology companies approaching commercialization. uniQure can invest in regulatory work, manufacturing, the required confirmatory study and launch infrastructure without an immediate dependence on another major capital raise.

Spending is nevertheless increasing. Second-quarter research and development expenses reached approximately $34 million, while selling, general and administrative expenses rose to $17.4 million as the company added capabilities connected with potential commercialization. uniQure reported a quarterly net loss of $81.1 million.

AMT-130 therefore needs to justify a growing level of investment before generating product revenue. Building a commercial model around direct brain administration will require fewer treatment centers than a mass-market drug launch, but each center will need significant expertise and logistical support.

The company also retains a broader neurological gene therapy pipeline, including AMT-260 for refractory mesial temporal lobe epilepsy. AMT-130 remains overwhelmingly the most important near-term value driver, however, because approval could transform uniQure from a development-focused biotechnology company into a commercial rare-neurology business.

uniQure shares reverse premarket gains as investors look beyond submission toward the FDA decision

Investor reaction illustrates how much of the submission itself had already been anticipated. Reuters reported that uniQure shares initially gained approximately 5% in premarket trading after the application was announced, but the stock reversed after the opening bell.

uniQure shares were quoted around $46.31 shortly before the September 2 close, down approximately 3.25% from the previous close of $47.86 after trading as high as $50.97 earlier in the session. Trading volume was modestly above its recent average.

The reversal resembles a market reassessment of what information the filing actually adds. Investors have known since June that the FDA would permit uniQure to submit the existing dataset under the accelerated approval pathway, so completion of the application removes an execution milestone without resolving the largest remaining regulatory uncertainty.

The stock has already undergone dramatic repricing over the past year. uniQure’s market capitalization was approximately $3.3 billion entering September, more than double its value at the end of 2025, showing how heavily the market is now assigning value to AMT-130.

Analyst sentiment remains favorable. S&P Global data compiled by StockAnalysis show 12 analysts with a consensus Strong Buy rating and an average price target of $70.04. Individual targets range from roughly $47 to $97, a wide spread that reflects considerable disagreement about regulatory probability and the eventual commercial value of AMT-130.

The upcoming four-year clinical update may therefore matter more to near-term sentiment than the completed filing. Continued separation from natural-history controls without new safety concerns would strengthen the durability argument during regulatory review, while weaker results could make investors more cautious about the evidence supporting accelerated approval.

AMT-130 has now reached the point where the scientific, regulatory and commercial questions converge. uniQure has submitted the application, secured enough capital to prepare for launch and obtained an unexpectedly favorable regulatory pathway after earlier setbacks. The FDA must now determine whether a relatively small but potentially transformative dataset provides enough evidence to make the first disease-modifying Huntington’s therapy available while confirmatory testing continues.

Key takeaways from uniQure’s AMT-130 FDA filing and the Huntington’s disease approval opportunity

• uniQure has submitted AMT-130 for accelerated FDA approval in Huntington’s disease and filed a parallel application in the United Kingdom.
• The company has requested Priority Review, which could shorten the FDA review timeline if the application is accepted and the request is granted.
• Three-year data showed a statistically significant 75% slowing of disease progression with high-dose AMT-130 compared with matched natural-history controls.
• Total Functional Capacity deterioration was slowed by 60%, providing additional evidence across an important measure of patient independence.
• The regulatory application relies primarily on Phase I/II data and an external-control comparison rather than a conventional randomized Phase III efficacy trial.
• The FDA reversed an earlier position requiring a new sham-controlled study and subsequently allowed the existing three-year analysis to support an accelerated approval filing.
• Four-year clinical data expected shortly could provide an important durability update while the application enters regulatory review.
• uniQure held approximately $810 million in cash and investments at the end of June and expects its financial runway to extend into 2030.
• uniQure shares reversed an early gain after the submission and traded about 3% lower shortly before the September 2 close as investors looked toward the actual FDA review.
• FDA acceptance, Priority Review, four-year data and the design of the confirmatory study now represent the most important catalysts for AMT-130 and uniQure.